BD buys reagent-maker Sirigen Group; J&J recalls discontinued custom implants;

 @FierceMedDev: It's a good day to be CardioDx. The company pulled in $58M in new financing. News | Follow @FierceMedDev

 @MarkHFierce: Cook Medical opens a new plant today in Illinois. Article | Follow @MarkHFierce

 @DamianFierce: The first wave of renal denervation devices have impressed docs in the EU. Report | Follow @DamianFierce

> Becton, Dickinson and Company ($BDX), a medical devices, instrument and reagent manufacturer, has snatched up Sirigen Group, a manufacturer of "unique polymer dyes." Neither side disclosed financial terms. Release

> Sophono, a Boulder, CO-based maker of implantable, bone conduction hearing devices, has raised $7 million in new financing. Item

> Maquet Cardiovascular generated mixed results in a clinical trial involving its intra-aortic balloon counterpulsation therapy for heart attack patients. Release

> Medtronic ($MDT) released the results of a long-term safety study of its drug-eluting stents, finding low rates of blood clot formation in patients treated for coronary artery disease. More

> Johnson & Johnson's ($JNJ) DePuy Orthopedics unit has recalled all of its unused custom implants, a business it discontinued in January. News

> Blockade Medical said it has treated the first patients with its Barricade Coil System, a device designed to treat cerebral aneurysms. Release

> HeartFlow says a new study shows its fractional flow reserve technology, used with CT angiography, more accurately determines which patient's blocked arteries need surgical attention than when using CT alone. Release

Biotech News

 @FierceBiotech: Analysis: For Eli Lilly's solanezumab, take 2 doesn't look so pretty. More | Follow @FierceBiotech

 @JohnCFierce: FDA wants a rewrite on Lemtrada app? Bit of an embarrassment for Genzyme and its overseers at Sanofi. Report | Follow @JohnCFierce

 @RyanMFierce: Ex-Google guys eye clinical trials with startup Flatiron. Story | Follow @RyanMFierce

> Merck readies apps for two cardio drugs. Article

> Promising T-DM1 clears PhIII cancer study and marches on to the FDA. Story

> Idenix plunges after FDA puts another hep C treatment on hold. News

> ESC Round-up: Head-to-head flop for Eli Lilly, PhII bonus for Novartis cardio drug. More

Pharma News

 @FiercePharma: Interested in the new GSK site at Philly's Navy Yard? 22 pics of construction in progress--via Philadelphia Business Journal. Gallery | Follow @FiercePharma

> Roche makes a tax deal on doomed Nutley site. More

> Lilly's Effient hopes dashed by head-to-head Plavix trial. Article

> Hospira adding 200 jobs at NC plant. News

> No more bids for Par Pharma, so $1.9B deal with TPG stands. Report

Biotech IT News

> Groups craft algorithms to rank drug contenders. Story

> Sanofi takes wisdom of crowd in social media blitz. Item

> Ex-Google guys eye clinical trials with startup Flatiron. News

> Amazon targets pharma R&D, others with new cloud storage. More

> Boehringer sets launch date for pharma's first social game on Facebook. Article

CRO News

> Chinese CRO Tigermed completes $80M IPO. Item

> West to open CMO facility in India. Story

> Pfizer backs out of generics deal with India's Claris. News

> PRA expands its Chinese presence as market swells. Article

> Researchers bristle at India's proposed trial reforms. Story